SEARCH:   Advanced

Blood, 1 August 2004, Vol. 104, No. 3, pp. 655-658. Prepublished online as a Blood First Edition Paper on April 8, 2004; DOI 10.1182/blood-2003-07-2345. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-07-2345v1 104/3/655    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lenihan, D. J. Articles by Duvic, M. Search for Related Content PubMed PubMed Citation Articles by Lenihan, D. J. Articles by Duvic, M. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome Daniel J. Lenihan, Alvaro J. Alencar, Deborah Yang, Razelle Kurzrock, Michael J. Keating, and Madeleine Duvic From the Departments of Cardiology, Dermatology, Leukemia, and Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston. Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sézary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Guglin, M. Aljayeh, S. Saiyad, R. Ali, and A. B. Curtis Introducing a new entity: chemotherapy-induced arrhythmia Europace, October 3, 2009; (2009) eup300v1. [Abstract] [Full Text] [PDF] M. H. Chen, R. Kerkela, and T. Force Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics Circulation, July 1, 2008; 118(1): 84 - 95. [Full Text] [PDF] A. Saad, R. Beto, J. Abraham, and S. C. Remick Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents ASCO Educational Book, January 1, 2008; 2008(1): 428 - 434. [Abstract] [Full Text] [PDF] M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients Haematologica, June 1, 2007; 92(6): 784 - 794. [Abstract] [Full Text] [PDF] I. Marie, S. Robaday, J.M. Kerleau, F. Jardin, and H. Levesque Typhlitis as a complication of alemtuzumab therapy Haematologica, May 1, 2007; 92(5): e62 - e63. [Abstract] [Full Text] [PDF] R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773. [Abstract] [Full Text] [PDF] J. Lundin, B. Kennedy, C. Dearden, M. J. S. Dyer, and A. Osterborg No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome Blood, May 15, 2005; 105(10): 4148 - 4149. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020